Merck KGaA looks to M&A to bolster its 'rather slim' pipeline

Merck KGaA made its largest acquisition in a decade in April 2025 when it snapped up Connecticut rare disease specialist SpringWorks Therapeutics for $3.9 billion. Under new CEO Kai Beckmann, Merck KGaA is emphasizing M&A to stock its early- to mid-stage pharma pipeline, the company said in reporting its first quarter results. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources Podcasts Fierce Events Industry Events Webinars…

Source: FiercePharma